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Abstract
Background: Calculating the Charlson comorbidity index (CCI) from medical records is a time-consuming and
expensive process. The objectives of this study are to 1) measure agreement between medical record and claims
data for CCI in lung cancer patients and 2) predict health outcomes of lung cancer patients based on CCIs from
both data sources.
Methods: We studied 392 patients who underwent surgery for pathologic stages I-III of lung cancer. The kappa
value was used to measure the agreement between the 17 comorbidities of the CCI prevalence obtained from
medical records and claims data. Multiple linear regression analyses were used to evaluate the relationships
between CCI and length of stay and reimbursement cost.
Results: Out of 17 comorbidities identified in the Charlson comorbidity index, ten had a higher prevalence, four
had a lower prevalence and three had a similar prevalence in claims data to those of medical records. The kappa
values calculated from the two databases ranged from 0.093 to 0.473 for nine comorbidities. In predicting length
of stay and reimbursement cost after surgical resection for lung cancer patients, the CCI scores derived from both
the medical records and claims data were not statistically significant.
Conclusions: Poor agreement between medical record data and claims data may result from different motivations
for collecting data. Further studies are needed to determine an appropriate method for predicting health
outcomes based on these data sources.
Background
Risk adjustment in clinical and health services research
studies has been advocated because the effects of con-
founding factors in nonrandomized studies can be
removed or reduced by adjusting the outcome measures
according to risk [1]. The severity and comorbidities can
be assessed to remove any potential causative factors for
the observed variations in health outcomes between
groups in order to differentiate treatment effects [2].
The Charlson comorbidity index (CCI) consists of 19
comorbid conditions weighted according to the degree
to which they predict mortality among an inpatient
cohort, and then the scores are summed to produce an
index score [3,4]. The Charlson comorbidity index was
developed based solely on the assessment of medical
records. However, despite the widespread use of medical
records, there is an inherent concern that there is a
selection bias in the results. The differences in the type
and number of comorbidities can result from the num-
ber of physician visits and the number of hospitaliza-
tions rather than an actual difference in comorbidities.
In addition, a retrospective analysis of medical records
would require great time investment and expense for a
large cohort study. Therefore, an alternative data
resource must contain the necessary information regard-
ing comorbidities, and it must enable the performance
of data collection and analysis in an efficient manner [5].
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is easier than are the methods for other comorbidity
indices. Therefore, medical records, patient reports, and
claims databases are all potential data sources, though
investigators must evaluate the quality, availability, and
cost of each [6]. Claims-based measures of comorbidity
are of particular importance to cancer care researchers,
who increasingly use population-based cancer registry
data linked with administrative claims to examine such
issues as the associations among treatment, health
expenditure, and survival [7].
The situation is similar in Korea. Based on the current
privacy laws of Korea, access to medical records has
been restricted for researchers. Though Korea has its
own cancer registry, due to an insufficient amount of
overall clinical information such as the comorbidities,
use of the cancer registry data alone is not appropriate.
As a result, attempts have been made to develop meth-
ods for adjusting the risks using the claims data. Though
accuracy of disease coding has been questioned given
the purpose of claims data, it could be a useful data
source owing to its coverage [8]. Especially in Korea,
more than 96% of the total Korean population is cov-
ered by national health insurance, and all national health
insurance claims are reviewed by the Health Insurance
Review & Assessment Service (HIRA), claims data of
HIRA provides a fair representation of entire patient
groups in Korea [9,10].
In this study, we compared the CCIs derived from
medical chart review versus those based on claims data,
and we examined whether the CCI scores obtained from
the two data sources could predict the length of stay
and the medical expenses, particularly for reimburse-
ment cost by HIRA, in patients who underwent surgery
for lung cancer.
Methods
Patients and CCI scoring method
Inpatient and outpatient medical records of patients
who were initially diagnosed with lung cancer during a
period ranging from January 1, 2000 to December 31,
2004 at the National Cancer Center were examined. We
primarily selected patients who were preoperatively
diagnosed with stage I to III disease, underwent surgery,
and were 18 years of age or older. From 461 patients, 69
patients were excluded from the statistical analysis,
because cancer stage or surgical treatment types of 64
patients were ill defined and five patients were diag-
nosed as state IV after the operation.
The final number of patients included in the study
was 392, and the Charlson comorbidity conditions were
collected using the Korean version of the CCI [11].
Additional clinical data collected from these patients
included age, gender, pathologic stage, histologic type,
surgical treatment modalities, frequency of surgery, sur-
gical methods, date of operation, date of initial diagnosis
of lung cancer and date of discharge. Comorbidities
were considered to be present in cases in which any
condition was confirmed more than once in the outpati-
ent or inpatient medical records up to two years prior
to the diagnosis of lung cancer. The medical records
were analyzed by medical doctors in the Department of
Family Medicine at the National Cancer Center from
November 2007 to February 2008.
To calculate CCI values from the claims data, we col-
lected the outpatient and hospitalization data for the
same subjects using the Electronic Data Interchange
(EDI) request data between 1999 and 2005. Information
such as the date of treatment initiation, primary and
secondary diagnosis codes, and reimbursement cost
were gathered from the claims data of 392 subjects.
ICD-10 codes are used in Korea. Therefore, definitions
of 17 comorbidities were adopted using an ICD-10 algo-
rithm for CCI, developed by Quan et al. [12]. Based on
the CCIs calculated using the claims data, comorbidities
were determined according to ICD-10 codes. By assign-
ing the weighted CCI values to the corresponding dis-
eases, the sums of the scores were determined to be the
final CCI scores.
We examined the EDI data from the two years pre-
ceding the initial date of confirmation of lung cancer
codes [C33-C34] at the National Cancer Center, and
then we confirmed the presence of comorbidity as
defined by Charlson comorbidity conditions claimed to
the HIRA for primary or secondary diagnoses. The EDI
data were collected from all of the medical institutions
in the country including the National Cancer Center. To
enhance the diagnostic accuracy of comorbidities in
claims data, a rule-out algorithm proposed by Klabunde
et al. was applied [6]. This algorithm states that any
condition confirmed more than twice in the data that
was collected during the same period is considered to
be comorbidity [6]. This study was approved by the
Institutional Review Board of the National Cancer
Center.
Outcome definition
To estimate the reimbursement costs that were
requested between the date of operation and the date of
discharge, we summed the costs requested within a one-
month period after the date of discharge at the National
Cancer Center. Cost was transformed into a logarithm
for analysis because of the right-skewed distribution of
cost. The length of stay was considered to be the date
of operation to that of discharge [13]. The length of stay
also had a right-skewed distribution and was converted
into a normal distribution via logarithmic transforma-
tion. In a model assessing the predictive validities of
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records and claim data, which were obtained for each
individual patient, were categorized according to three
scales: 0, 1 and 2 or greater. These CCI scales were
selected as the independent variables for health out-
comes. Also we considered age, gender, histologic types
of cancer, surgical treatment modalities and pathologic
disease stages (stage I, II, III) as adjustable variables, as
they have been reported to be prognostic factors of lung
cancer in previous studies [14-16].
Statistical analysis
The agreement between medical records and claims data
on CCI was assessed based on simple agreement rate
and kappa statistics. We performed a multiple linear
regression analysis to evaluate whether CCI could pre-
dict length of stay and reimbursement cost [17]. All sta-
tistical analyses were performed using the Stata/SE 9.0
software package, and statistical significance was tested
at a value of p < 0.05.
Results
Agreement between medical records and administrative
data
The prevalence of 17 comorbidities and the agreement
rate between the two data resources were analyzed from
CCIs based on medical records and claims data, and the
results are presented in Table 1.
In cases of myocardial infarction, congestive heart fail-
ure, peripheral vascular diseases, chronic pulmonary dis-
ease, rheumatoid diseases, peptic ulcer diseases, mild
hepatic diseases, complicated diabetes mellitus, and
metastatic solid cancer, the comorbidities of claims data
were more prevalent than were the medical records
data. In cases of primary cancer excluding skin cancer,
quadriplegia, and hemiplegia, there were similar fre-
quencies between the two data resources. Moreover, the
prevalence of dementia and AIDS were 0% in both
datasets.
To assess the agreements for 17 comorbidities
between the medical records and claims data, kappa sta-
tistics and agreement rate were used. To calculate the
kappa value, none of the cell frequencies should be zero,
although this was observed in eight comorbidities of our
study. Hence, the kappa value was calculated based on
nine comorbidities. The agreement rate ranged from
66.07% to 100% for each disease, with chronic pulmon-
ary disease having the lowest agreement rate. The kappa
analysis revealed that the kappa value of four diseases,
myocardial infarction, cerebrovascular disease, uncom-
plicated diabetes mellitus, and any malignancy except
skin neoplasm, illustrated to fair agreement. In the
Table 1 Agreements between medical records and claims data (unit = n (%))
Comorbidity Prevalence
medical records
data
Prevalence
administrative
data
Agreement between data sources (Medical
record/Administrative data)
Kappa(SE) Agreement
rate
Yes/Yes No/No Yes/No No/Yes
Myocardial infarction 4(1.0) 5(1.3) 1(0.3) 384(98.0) 3(0.8) 4(1.0) 0.213(0.050) 98.21
Congestive heart failure 1(0.3) 9(2.3) 0(0.0) 382(97.4) 1(0.3) 9(2.3) NA
c 97.45
Peripheral vascular disease 1(0.3) 11(2.8) 0(0.0) 380(96.9) 1(0.3) 11(2.8) NA
c 96.94
Cerebrovascular disease 23(5.9) 21(5.4) 11(2.8) 359(91.5) 12(3.1) 10(2.6) 0.473(0.050) 94.39
Dementia 0(0.0) 0(0.0) 0(0.0) 392(100.0) 0(0.0) 0(0.0) NA
b 100.00
Chronic pulmonary disease 29(7.4) 138(35.2) 17(4.3) 242(61.7) 12(2.1) 121(30.9) 0.093(0.034) 66.07
Rheumatic disease 3(0.8) 10(2.6) 1(0.3) 380(96.9) 2(0.5) 9(2.3) 0.144(0.042) 97.19
Peptic ulcer disease 13(3.3) 91(23.2) 4(1.0) 292(74.5) 9(2.3) 87(22.1) 0.020(0.031) 75.51
Mild liver disease 9(2.3) 43(11.7) 6(1.5) 343(87.5) 3(0.8) 40(10.2) 0.187(0.036) 89.03
Diabetes without chronic
complication
53(13.5) 15(3.8) 11(2.8) 335(85.5) 42(10.7) 4(1.0) 0.281(0.041) 88.27
Diabetes with chronic
complication
6(1.5) 21(5.4) 3(0.8) 368(93.9) 3(0.8) 18(4.5) 0.203(0.041) 94.64
Hemiplegia or paraplegia 1(0.3) 1(0.3) 0(0.0) 390(99.5) 1(0.3) 1(0.3) NA
c 99.49
Renal disease 2(0.5) 0(0.0) 0(0.0) 390(99.5) 2(0.5) 0(0.0) NA
a 99.49
Any malignancy, except
malignant neoplasm of the
skin
10(2.6) 11(2.8) 4(1.0) 375(95.7) 6(1.5) 7(1.8) 0.364(0.050) 96.68
Moderate or severe liver
disease
2(0.5) 1(0.3) 0(0.0) 389(99.2) 2(0.5) 1(0.3) NA
c 99.23
Metastatic solid tumor 0(0.0) 1(0.3) 0(0.0) 391(99.7) 0(0.0) 1(0.3) NA
a 99.74
AIDS/HIV 0(0.0) 0(0.0) 0(0.0) 392(100.0) 0(0.0) 0(0.0) NA
b 100.00
aComorbidity was present in only one source;
bComorbidity was absent in both sources;
cThe cell frequency is 0.
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monary disease, rheumatoid diseases, peptic ulcer dis-
eases, mild hepatic diseases, and complicated diabetes
mellitus, the kappa value showed poor agreement. The
concordance rates of the CCI scores between the two
data resources are shown in Table 2. Agreement for
CCI scores calculated by assigning comorbidities with
weighted values had a kappa value of 0.054 (standard
error = 0.029). For CCI scores categorized into three
scales (i.e., 0, 1, 2+), the kappa statistic was 0.096 (stan-
dard error = 0.032). This indicates that the agreement
was slightly increased, although it was still poor.
According to the distributions of CCI scores between
the two data resources, we observed that 196 patients
(50.0%) had higher CCI scores as determined using the
claims data than for that calculated using the medical
records, with 45 patients (11.5%) having lower scores.
Subject characteristics
For 392 patients who underwent surgery for lung cancer,
the mean age was 60.9 years (standard deviation = 8.8
years). The number of male patients was 291 (74.2%),
accounting for the majority of patients (Table 3).
Prediction for length of stay
For the length of stay prediction adjusted by age, gen-
der, histologic differentiation of the cancer, surgical
treatment modalities, and pathologic stage, the CCI
scores based on medical records and claims data are
shown in Table 4. The CCI scores derived from either
database were not prognostic for length of stay after
adjusting for age, gender, histologic differentiation of the
cancer, surgical treatment modalities, and pathologic
stage. However, length of stay significantly increased by
1.15 times (95% CI 1.005-1.314) with pathologic stage 3
lung cancer in the claims data model.
Prediction for reimbursement cost
Based on the medical records and claims data, a multi-
ple linear regression analysis was performed to examine
the predictive power of CCI-based reimbursement cost.
After adjusting for age, gender, histologic differentiation
of the cancer, surgical treatment modalities, and patho-
logic stage, CCI scores were not selected as a prognostic
factor. The only reimbursement cost was significantly
higher at pathologic stage 3 of lung cancer by 1.15
times in claims data based model (95% CI 1.020-1.295)
(Table 5).
Discussion
CCI was originally developed based on data derived
from medical records. However, many researchers have
proposed that the sole dependence on medical records
results in a limitation in cases for which a prompt risk
assessment is required by hospitals, insurers and Health
Management Organizations (HMOs) [18]. Therefore,
CCI tools have been developed for use with claims data
coded using ICD-9-CM (International Classification of
Diseases, 9th revision, Clinical Modification) [19,20] and
ICD-10 (Switzerland, Australia, Canada versions)
[12,21,22].
However, the consistency between medical records
and claims data is not excellent. For 485 patients who
underwent prostatectomy, the comorbidities based on
the medical records and claims data were compared.
The kappa value was greater than 0.61 for five diseases
(uncomplicated diabetes mellitus, primary solid tumor,
moderate hepatic disease, connective tissue diseases, leu-
kemia), but the remaining diseases had poor agreement
[23]. Also Newschaffer et al. compared CCI scores
between the medical records and claims data in 404
patients with breast cancer. This comparison revealed
that the kappa value was 0.36, corresponding to ‘fair
agreement’ [24].
In a Korean study that targeted patients who under-
w e n ts u r g e r yf o rt h et r e a t m e n to fg a s t r i cc a n c e r ,t h e
kappa value of CCI comorbidities between the data
resources was fair for five diseases; however, excluding
these comorbidities, the kappa value was less than 0.2.
E s p e c i a l l yt h ep r e v a l e n c eo fp e p t i cu l c e rd i s e a s ew a s
41.6% according to the claims data and 3.5% according
to the medical records data [25]. Another study, which
focused on patients who underwent hip joint arthro-
plasty, reported that the kappa value of comorbidities
for two data resources was 0.8 for metastatic solid
tumors and 0.51 for uncomplicated diabetes mellitus. In
other comorbidities, the kappa value was smaller than
0.29 [26]. In this study, there were discrepancies
between the two data sources, supporting the results
from previous studies in Korea and other countries.
Table 2 Agreement in Charlson comorbidity index score
between medical records and claims data
Claims data CCI score Medical records CCI score Total
01 2 3 4 5
0 122 26 3 3 0 0 154
19 0 22 6 1 0 0 119
24 1 2 4 5 30 0 7 3
31 4 1 1 6 2 03 3 6
42 1 1 1 0 05
51 2 0 0 1 0 4
80 0 0 1 0 0 1
Total 270 86 21 11 1 3 392
Note: kappa = 0.054 (SE 0.029) (agreement rate = 38.52%). Bold characters
represent a complete concordance of the frequency between the medical
record and claims data.
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there is an underestimation of CCI comorbidities based
on medical records data. Medical records based on CCI
scores were retrospectively obtained from the one medi-
cal institution, whereas claims data based on CCI scores
were gathered from administrative data, which includes
all medical institutions’ claims data on the selected
patient. In addition, poor agreement between medical
record data and claims data may result from the differ-
ing motivations for data collection between medical
records and claims data.
Inconsistencies have also been observed in previous
studies investigating whether CCI scores obtained from
claims data could be used to predict the length of hospi-
tal stay. According to a study of 20,138 patients who
underwent surgery for radical urological cancer, the
length of stay was prolonged by approximately 1-2 days
in the group in whom CCI scores were at least 1 com-
pared to the groups with 0 points [27]. In another
study, 1,216 patients who visited an outpatient clinic
with a chief complaint of acute chest pain, compared
with the group in which CCI scores were calculated to
be 0-1 points from the medical records, the length of
stay was delayed by 14.4-fold (95%CI 3.9-25.9) in the
group in which CCI scores were calculated to be 2-3
points and by 25.3-fold (95%CI 2.4-25.5) in the group in
which CCI scores were calculated to be < 4 points [28].
However, in 1,945 patients who underwent carotid
endarterectomy, CCI scores based on claims data did
not correlate with the length of stay, though CCI scores
based on medical records were associated with an
increased length of stay [1]. In the current study,
according to a length of stay prediction model, CCI
scores calculated using medical records and claims data
were not shown to be prognostic factors. This may be
due to the fact that CCI was originally developed to pre-
dict mortality, and it is simply not an appropriate tool
for predicting length of stay [29]. Also, the postoperative
length of stay may be dependent on the severity of the
procedure rather than comorbidities [27].
Moreover, there were disagreements in the predictability
of CCI with regard to reimbursement cost. In a medical
record-based study of dialysis patients, the mean medical
expense per year was $54,000 in cases in which CCI scores
were calculated to be less than 4 points, $108,000 in those
where CCI scores were calculated to be 4-5 points,
Table 3 Patient characteristics and operative characteristics (n = 392)
Characteristics n%
Age[year] ≤ 49 46 11.7
50-59 108 27.6
60-69 169 43.1
≥ 70 67 17.1
Mean ± SD 60.9 ± 8.8
Gender male 291 74.2
female 101 25.8
One-year mortality alive 384 98.0
dead 8 2.0
Three-year mortality alive 358 91.3
dead 34 8.7
Surgical treatment type wedge resection 12 3.1
lobectomy 336 85.7
pneumonectomy 41 10.5
other 3 0.8
Pathologic stage I 206 52.6
II 76 19.4
III 110 28.0
Histologic subtype
a squamous cell carcinoma 204 53.0
adenocarcinoma 155 40.3
bronchoalveolar carcinoma 17 4.4
large cell carcinoma 2 0.5
small cell carcinoma 3 0.8
other 4 1.0
Length of stay (days) Mean ± SD 37.60 ± 46.32
Mean reimbursement cost(won) Mean ± SD 5,240,683 ± 2,318,995
aSeven patients were missing histologic subtype.
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6-7 points and $407,000 in those where CCI scores were
calculated to be 8 or more points. These differences were
found to be statistically significant (p < 0.0001) [30]. How-
ever, CCI scores did not correlate with medical expense in
head-and-neck cancer patients [31]. In our study, accord-
ing to a reimbursement cost prediction model that was
established based on the medical records and claims data
as related by CCI, CCI was not selected as a prognostic
factor for either model. This could be attributed to the
fact that the prediction model was developed for death
hazards [29].
This study has several limitations. First, medical
records based on the CCI scores of selected patients
were retrospectively obtained from the records of the
National Cancer Center. However, claims data based on
the CCI scores of selected patients were gathered from
HIRA, which includes all medical institutions’ claims
data on the selected patients. But this could be regarded
as strength of claims data in terms of accessibility and
efficiency. Second, we considered the reimbursement
cost of claims data only with respect to the availability
of data. As a result, other medical expenses, such as
non-covered services, were excluded. Also, the
reimbursement cost was calculated as the sum of the
medical costs from the date of surgery to one month
after the date of discharge. Therefore, it is possible that
outpatient visits except follow-up cancer treatment
within a one-month period after discharge may have
been included. Also though we considered some prog-
nostic factor such as pathologic staging, there are other
prognostic factors such as smoking or adjuvant che-
motherapy. More information about such factor could
affect the health outcomes and the predictability of CCI.
In this study, there was poor agreement between med-
ical records and claims data. In addition, CCIs based on
both data sets were not suitable for predicting length of
stay or medical expenses. Given how easy it is to calcu-
late CCIs based on claims data, especially in a social
health insurance system, there should be further studies
to improve methods for calculating CCI scores to pre-
dict health outcome.
Conclusions
Considering the difficulty of accessing medical records
in the presence of privacy protection laws, the use of
claims data to calculate CCI is a very attractive and
potentially useful method. Claims data can also be used
Table 4 Prediction for length of stay using medical records and claims data-based comorbidity index score
Exp[coefficient] based on
medical records
95% Confidence
interval
Exp[coefficient] based on
claims data
95% Confidence
interval
Age[years] ≤ 49 1 1
50-59 1.06 (0.880-1.295) 1.06 (0.871-1.282)
60-69 1.2 (1.000-1.448) 1.19 (0.986-1.427)
≥ 70 1.07 (0.866-1.328) 1.05 (0.846-1.305)
Gender male 1 1
female 0.96 (0.832-1.113) 0.96 (0.833-1.116)
Histologic
subtype
squamous cell
carcinoma
11
adenocarcinoma 0.95 (0.834-1.094) 0.96 (0.839-1.101)
bronchoalveolar
carcinoma
1.1 (0.827-1.471) 1.1 (0.827-1.473)
large cell carcinoma 0.79 (0.372-1.675) 0.8 (0.377-1.709)
small cell carcinoma 1.21 (0.654-2.268) 1.19 (0.640-2.227)
other 0.94 (0.552-1.626) 0.96 (0.558-1.639)
Surgical
treatment type
wedge resection 1 1
lobectomy 1.15 (0.832-1.607) 1.18 (0.851-1.641)
pneumonectomy 0.98 (0.674-1.438) 1.01 (0.688-1.469)
other 1.43 (0.721-2.864) 1.46 (0.729-2.913)
Pathologic stage I 1 1
II 0.96 (0.832-1.123) 0.97 (0.838-1.132)
III 1.13 (0.993-1.302) 1.15* (1.005-1.314)
CCI score 0 1 1
1 0.92 (0.809-1.062) 0.99 (0.863-1.128)
2+ 0.94 (0.775-1.144) 1 (0.872-1.142)
*p < 0.05 according to multiple linear regression analysis using log-transformed length of stay
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can be collected easily by different medical institutions.
However, in this study, the agreement of CCIs based on
the two datasets was not sufficient, and CCIs from
neither data set were able to predict length of stay or
medical expenses. Therefore, improvement and modifi-
cation are needed to successfully use CCI scores based
on claims data, at least in the case of lung cancer.
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